EP2456520B1 - System zur behandlung von krebs mittels einer brachytherapie - Google Patents

System zur behandlung von krebs mittels einer brachytherapie Download PDF

Info

Publication number
EP2456520B1
EP2456520B1 EP10802986.9A EP10802986A EP2456520B1 EP 2456520 B1 EP2456520 B1 EP 2456520B1 EP 10802986 A EP10802986 A EP 10802986A EP 2456520 B1 EP2456520 B1 EP 2456520B1
Authority
EP
European Patent Office
Prior art keywords
tandem
ovoids
ovoid
patient
inflatable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10802986.9A
Other languages
English (en)
French (fr)
Other versions
EP2456520A2 (de
EP2456520A4 (de
Inventor
Javad Rahimian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voxel Rad Ltd
Original Assignee
Voxel Rad Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voxel Rad Ltd filed Critical Voxel Rad Ltd
Publication of EP2456520A2 publication Critical patent/EP2456520A2/de
Publication of EP2456520A4 publication Critical patent/EP2456520A4/de
Application granted granted Critical
Publication of EP2456520B1 publication Critical patent/EP2456520B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
    • A61B17/0206—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors with antagonistic arms as supports for retractor elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/02—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors
    • A61B17/0218—Surgical instruments, devices or methods, e.g. tourniquets for holding wounds open; Tractors for minimally invasive surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1007—Arrangements or means for the introduction of sources into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1014—Intracavitary radiation therapy
    • A61N5/1016—Gynaecological radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00535—Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated
    • A61B2017/00557—Surgical instruments, devices or methods, e.g. tourniquets pneumatically or hydraulically operated inflatable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3966—Radiopaque markers visible in an X-ray image
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1002—Intraluminal radiation therapy
    • A61N2005/1003—Intraluminal radiation therapy having means for centering a radioactive source within the lumen, e.g. balloons

Definitions

  • the present application relates to devices for treating cancer using brachytherapy.
  • the present application relates to devices for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator.
  • Brachytherapy typically offers low morbidity by delivering a high dose of ionizing radiation to the target volume, sparing surrounding healthy tissue with rapid dose fall off outside the implanted volume. Selective placement of the radioactive sources allow the dose distribution to be manipulated to match the target shape.
  • Brachytherapy can be used in treating most areas of the body and can be used alone or in conjunction with External Beam Radiotherapy, Chemotherapy, and Surgery for management of cancer.
  • HDR and LDR brachytherapy are well-established techniques with a long history of use in treatment of cervical and uterine cancers.
  • the scientific principle behind this technology is that a highly radioactive source inside an afterloader passes through a transfer guide tube into an applicator implanted in the patient.
  • the radioactive source is programmed to remain in its precise location for a given period to deliver radiation dose according to the prescription. This can be effective in treating cancers of the cervix and uterus.
  • FSD Fletcher-Suit-Delclos
  • intracavitary applicators based on the FSD applicator concept have been designed, and used in the clinic, e.g., the Week, Williamson, Henschke and Mick applicators.
  • the typical prescription requires 3 or 4 implants, one week apart, on the same patient.
  • the traditional FSD applicator normally consists of 8-pieces assembled as the patient rests supine in the stirrup position.
  • the current clinical procedure using FSD applicator is typically lengthy, painful, and often requires anesthetics, or conscious sedation.
  • the problems outlined herein have made patients request alternative treatments such as surgery or use of Intensity Modulated Radiotherapy (IMRT).
  • IMRT Intensity Modulated Radiotherapy
  • the intracavitary brachytherapy for treating cervical and uterine cancers should not be replaced with IMRT since intracavitary brachytherapy provides more conformal therapy, less integral dose, and superior sparing of the organs at risk.
  • US 6312375 discloses an intracavitary implant having a tandem and two colpostats, each colpostat including a housing portion adapted to receive a radiation source and a jacket defining a cavity sized to receive the housing portion.
  • the jacket defines a number of chambers configured to expand in volume to move a patient's rectum and bladder further from the radiation source, to increase the percent depth dose to parametrial tissue relative to a vagina and to adjust the relative positioning between the colpostats and the tandem.
  • the present application relates to devices for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator to harness the benefits of brachytherapy in addition to easing and improving the implant procedure.
  • Some embodiments comprise an advanced applicator system built for high and/or low dose rate (HDR and LDR) brachytherapy using a novel and innovative design with the aim of easier implantation of the applicator.
  • HDR and LDR high and/or low dose rate
  • a system for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator comprising:
  • Embodiments of the present application provide advantages over the Fletcher-Suit-Delclos (FSD) afterloading intracavitary brachytherapy applicators.
  • FSD Fletcher-Suit-Delclos
  • an applicator comprises a tandem catheter and comprises two colpostats arranged for introduction of radioactive sources for intracavitary brachytherapy.
  • the tandem can be integrated with an endoscope in some embodiments that gives the capability of locating the cervical os and guiding the tandem into the uterine canal.
  • the conventional FSD applicator colpostats are made of variously sized rigid caps.
  • the applicator comprises two inflatable ovoid balloons with the capability of expansion to multiple sizes through iodinated saline. To replace inadequate retraction offered by currently used vaginal packing, two additional semi-cylindrical balloons are preferably attached to the ovoid assembly for retracting the bladder and rectum to lower the radiation dose received by these organs.
  • the applicator preferably provides a geometrically optimum implant where the tandem is positioned to bisect the ovoids, the ovoids are inflated and positioned to the largest size appropriate to fit the anatomy of the patient, and the bladder and the rectum are pushed away from a plane of the implant by one or more retractors.
  • the retractors push the bladder and rectum away from a plane of the implant by at least two centimeters.
  • the applicator implements inflatable retractors for isolating the patient's bladder and the rectum from radioactive sources, lowering the radiation dosage absorbed by these critical structures.
  • An endoscope integrated with the tandem in some embodiments, can provide advantages such as, for example, locating the cervical os more easily, limiting uterine perforations, sounding the uterus, and guiding the tandem through the uterine canal.
  • an embodiment of the applicator having a tandem and a dual ovoid assembly.
  • the tandem may have a fiberoptic endoscope integrated with it, so the cervical os can easily be found instead of the patient being blindly poked with a speculum placed in the vaginal canal.
  • the tandem and the collapsed balloon dual ovoid assembly can easily be inserted as a single unit into the vaginal canal.
  • the tandem may be guided by endoscope into the cervical os and uterine canal, where the ovoids may be placed in the cervical fornices.
  • the ovoids can comprise two balloons that are inflated with desired volumes of iodinated saline.
  • the ovoids can conform to the cervical tumor and can provide adaptive brachytherapy.
  • the applicator can allow for the tandem and ovoids to be assembled and/or configured rapidly. Adjustments to the system can be completed outside of the patient, similar to a laproscopy procedure. Advantages of the applicator systems include simplification of the use of the implant, utilizing fewer parts, adjustable ovoids fitting the patient fornices with comfort, and the inflatable retraction mechanism to separate and give adequate distance to the bladder and rectum. This will optimize the dose to the cervix and uterus, minimizing the dose to these critical structures.
  • advantages of applicator systems and methods may include easier and faster implantation.
  • the applicator can cause less or no pain to the patient.
  • the applicator can reduce complications to the patient.
  • the applicator can have simple and integrated applicator parts. Methods of using the applicator and performing treatments can be reproducible.
  • the applicator can provide improved implant geometry.
  • the applicator can be configured to provide for manipulations to be done outside the vaginal and uterine canals, thus making the implant less invasive and geometrically advantageous.
  • the applicator can provide improved radiation dosimetry and lower dose to bladder and rectum.
  • a system for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator comprises a tandem adapted for insertion into a cervix of a patient.
  • the tandem comprises an endoscopic viewing element to facilitate treatment and one or more radiographic markers.
  • An ovoid assembly comprises first and second adjustably inflatable ovoids and an ovoid support mechanism.
  • the ovoid support mechanism is adapted to support the ovoids and to allow for user manipulation to control the relative position of the ovoids for insertion of the ovoids within the fornices of a patient.
  • the first and second adjustably inflatable ovoids have a deflated configuration for insertion into a patient and one or more adjustably inflated configurations for positioning the ovoid assembly during treatment.
  • the first and second ovoids each have one or more radiographic markers.
  • the ovoid assembly comprises a tandem connector adapted to releasably and adjustably couple the tandem to the ovoid assembly to allow for pivotal and translational motion of the tandem relative to the ovoid assembly and to limit rotational movement of the tandem about a longitudinal axis of the tandem.
  • First and second adjustably inflatable retractors are adapted to be releasably coupled to the ovoid assembly at first and second retractor connector portions.
  • the first and second inflatable retractors have a deflated configuration for insertion into a patient and an adjustably inflated configuration for retraction of tissue during treatment.
  • the first retractor is adapted to be positioned to retract the bladder of a patient during treatment and the second retractor is adapted to be positioned to retract the rectum of a patient during treatment.
  • the tandem and the first and second inflatable ovoids are adapted to be coupled to a radioactive source to deliver an implant radiation dose suitable for cancer treatment at a cancerous cervical treatment site in a patient.
  • a system for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator comprises a tandem adapted for insertion into a cervix of a patient.
  • An ovoid assembly comprises first and second inflatable ovoids and an ovoid support mechanism.
  • the first and second inflatable ovoids are adapted for insertion within fornices of a patient.
  • First and second retractors are adapted to be coupled to the ovoid assembly.
  • the first retractor is adapted to be positioned to retract the bladder of a patient during treatment and the second retractor is adapted to be positioned to retract the rectum of a patient during treatment.
  • the tandem and the first and second inflatable ovoids are adapted to be coupled to a radioactive source to deliver an implant radiation dose suitable for cancer treatment at a cancerous cervical treatment site in a patient.
  • a method of treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator comprises providing an intracavitary brachytherapy applicator having a tandem, an ovoid assembly comprising first and second inflatable ovoids and an ovoid support mechanism, and first and second retractors adapted to be coupled to the ovoid assembly.
  • the tandem is inserted into a cervix of a patient.
  • the first and second inflatable ovoids are inserted within fornices of a patient.
  • the first and second retractors are inserted within a patient.
  • the first and second inflatable ovoids are inflated within a patient.
  • the bladder of a patient is retracted from a treatment site.
  • the rectum of a patient is retracted from a treatment site.
  • An implant radiation dose suitable for treatment is delivered at a treatment site.
  • a method of treating cervical and/or uterine cancers in brachytherapy with an Intracavitary brachytherapy applicator can comprise one or more of the following steps.
  • First and second retractors can be coupled to the ovoid assembly prior to insertion within a patient.
  • the tandem and the first and second inflatable ovoids can be coupled to a radioactive source.
  • Retracting the bladder can comprise inflating the first retractor.
  • Retracting the rectum can comprise inflating the second retractor.
  • the tandem can be coupled to the ovoid assembly.
  • the tandem can be translated relative to the ovoid assembly.
  • the tandem can be pivoted relative to the ovoid assembly.
  • the tandem can comprise an endoscopic viewing element. A portion of the anatomy of the patient can be viewed with the viewing element upon insertion of the tandem within the patient. Rotational movement of the tandem about a longitudinal axis of the tandem can be limited by a connection between the tandem and ovoid assembly.
  • an intracavitary brachytherapy applicator has a tandem and first and second inflatable ovoids.
  • the tandem and ovoids are adapted to deliver an implant radiation dose for treatment of a patient.
  • the applicator comprises one or more retractors.
  • the ovoids are preferably coupled to an ovoid assembly to support the ovoids and to control the relative position of the ovoids.
  • the tandem is preferably releasably coupled to the ovoid assembly and is adjustable relative to the ovoid assembly.
  • the tandem preferably pivots and translates relative to the ovoid assembly.
  • the tandem is preferably coupled to the ovoid assembly in a manner that limits or restricts rotation of the tandem about a longitudinal axis of the tandem.
  • retractors are releasably coupled with the ovoid assembly.
  • retractors can be fixed or attached to the ovoid assembly.
  • a first retractor can be positioned to retract the bladder of a patient during treatment and a second retractor can be positioned to retract the rectum of a patient during treatment.
  • the retractors are preferably inflatable to at least partially retract the bladder and rectum from a treatment site. In some other embodiments the retractors are not inflatable.
  • the tandem is preferably integrated with an endoscope to facilitate treatment.
  • an advanced and minimally invasive cervical and uterine HDR and/or LDR applicator system comprises a tandem catheter adapted to be placed inside the uterine canal with two inflatable catheters placed next to the cervical fornices, while using two inflatable semi-cylindrical balloons to retract the bladder and rectum away from the radioactive sources.
  • the tandem central catheter can include endoscopic fiber optics to transmit images of the cervical os, as well as the uterine canal as it is placed. This can facilitate insertion, limit multiple pokes of the cervix, may limit injury to the cervix and uterine perforation causing injury and infection to the uterus as well as to the small bowel.
  • the endoscopic tandem and the dual ovoid assembly can be configured as a single piece that advantageously enables the radiation oncologist to implant the applicator possibly without a speculum, reducing pain, anesthetics, and stress on the nursing personnel and the radiation oncologist.
  • systems for treating cervical and/or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator 100 comprise a tandem 102 adapted for insertion into a cervix of a patient.
  • the tandem 102 can comprise an endoscopic viewing element 104 to facilitate treatment and one or more radiographic markers 106.
  • An ovoid assembly 110 comprises first and second adjustably inflatable ovoids 112, 114 and an ovoid support mechanism 116.
  • the ovoid support mechanism 116 is adapted to support the ovoids 112, 114 and to allow for user manipulation to control the relative position of the ovoids for insertion of the ovoids within the fornices of a patient.
  • the first and second adjustably inflatable ovoids 112, 114 have a deflated configuration for insertion into a patient and one or more adjustably inflated configurations for positioning the ovoid assembly during treatment.
  • the first and second ovoids 112, 114 each have one or more radiographic markers 120, 122.
  • the ovoid assembly 110 comprises a tandem connector 124 adapted to releasably and adjustably couple the tandem 102 to the ovoid assembly 110 to allow for pivotal and translational motion of the tandem 102 relative to the ovoid assembly 110 and to limit rotational movement of the tandem 102 about a longitudinal axis of the tandem.
  • First and second adjustably inflatable retractors 130, 132 are adapted to be releasably coupled to the ovoid assembly at first and second retractor connector portions 134, 136.
  • the first and second inflatable retractors 130, 132 have a deflated configuration for insertion into a patient and an adjustably inflated configuration for retraction of tissue during treatment.
  • the first retractor 130 is adapted to be positioned to retract the bladder of a patient during treatment and the second retractor 132 is adapted to be positioned to retract the rectum of a patient during treatment.
  • the tandem 102 and the first and second inflatable ovoids 112, 114 are adapted to be coupled to a radioactive source to deliver an implant radiation dose suitable for cancer treatment at a cancerous cervical treatment site in a patient.
  • the applicator systems can have one or more of the following advantageous characteristics in some embodiments.
  • Some embodiments include applicator systems 100 that can be preassembled before insertion into the patient such that only a few, and in some cases, preferably one or two adjustable and integrated pieces are inserted into the patient.
  • the current FSD applicators require about 8 pieces to be assembled while inserted within a patient during use. Accordingly, use of embodiments of the present application preferably makes insertion and manipulation of the implants faster, more dosimetrically optimal, lessens the need for anesthetics, and reduces pain to the patient.
  • the applicator system 100 comprises a pair of ovoids 112, 114 in the form of inflatable balloons, each with varying volume capacity, rather than solid caps of varying sizes currently used as colpostats.
  • the inflatable balloon ovoids 112, 114 can advantageously and naturally take on the shape of mini, small, medium, and/or large size ovoids depending on the size of the patient's anatomy.
  • the ovoids 112, 114 can be independently inflated to 4 different sizes of the following approximate dimensions: SIZE WIDTH LENGTH VOLUME Mini 1.4cm 3.0 5cc Small 2.0cm 3.0 10cc Medium 2.5cm 3.0 15cc Large 3.0cm 3.0 21cc
  • the two ovoids 112, 114 can be inflated with different volumes.
  • one ovoid can be inflated as small size and the other as medium size ovoid.
  • the left and the right side ovoids are preferably substantially identical in size, even though at the radiation oncologist's and/or the physicist's discretion, one can be inflated larger than the other depending on the extent of the disease and size of the fornices.
  • the ovoids can have different maximum sizes.
  • the ovoid support mechanism 116 is adapted to support the ovoids 112, 114 and to allow for user manipulation to control the relative position of the ovoids for insertion of the ovoids within the fornices of a patient.
  • the ovoid support mechanism 116 supports first and second catheter shafts 140, 142 coupled with the ovoids for delivering radiation to the ovoids.
  • the ovoid support mechanism also comprises first and second handle portions 144, 146 coupled for pivotatal movement relative to one another. Movement of the handle portions 144, 146 relative to each other controls the distance between the first and second ovoids 112, 114.
  • the relative position of the handle portions 144, 146 can be fixed by tightening a knob 150 at an upper portion of the ovoid support mechanism 116.
  • a lower portion of the ovoid support mechanism 116 comprises the tandem connector 124.
  • the tandem connector 124 comprises a slot 152 for receiving the tandem 102, a spring loaded ball or pin 154 on a first side of the slot 152 and a flat surface 156 on a second side of the slot 152.
  • the tandem 102 comprises a groove 160 for translationally and pivotally coupling to the spring loaded ball or pin 154 when the tandem is positioned in the slot 152.
  • a flat surface 162 of the tandem is positioned opposite the groove 160 and interfaces with the flat surface 156 of the tandem connector 124 when the tandem is positioned in the slot 152 to limit rotational movement of the tandem 102 about a longitudinal axis.
  • Tandems 102 can have different shapes and configurations. For example, some embodiments include tandems having a curved portion 164 of 0, 15, 30, 45, and 60 degrees. The tandem 102 can be provided with or without endoscopic capabilities. Additionally, a tandem 102 can include radiographic markings, for example, one-cm markings, on it for measurement and/or viewing. The markers 106 can be positioned near the tandem tip 166 and/or near the tandem connector portion 124. The tandem 102 and the ovoids 112, 114 are coupled to catheter shafts 138, 140, and 142, respectively. The total internal length of the catheters 138, 140, and 142 are preferably substantially identical for both the tandem 102 and the ovoids 112, 114.
  • the total lengths can vary.
  • the internal length of the catheter shafts 138, 140, 142 of the tandem 102 and the two ovoids 112, 114 is preferably about 35 cm. Longer or shorter catheter lengths are also contemplated.
  • a tandem connector 124 mechanism is provided for coupling the tandem 102 with the ovoid assembly 110.
  • the mechanism preferably enables the tandem 102 to pivot in the anterior/posterior direction about a point in reference to the ovoids 112, 114 using a spring-loaded ball bearing 154 within the ovoid assembly 110 to interface with a groove 160 on a side of the tandem as best seen in FIG. 13 .
  • the mechanism also preferably allows the user to translate and/or pivot the tandem to keep it at the mid-plane of the ovoids 112, 114 during treatment. Enabling the user to position the tandem 102 to bisect the ovoids 112, 114 helps to improve implant geometry and dose distribution.
  • a side of the tandem opposite the grooved side preferably has a flattened surface 162 that contacts a flattened surface 152 of the ovoid assembly 110 to limit inadvertent rotation of the tandem 102 during manipulation and treatment.
  • the mechanism preferably limits the tandem from rotatation around a longitudinal axis of the tandem and permits translational and pivotal motion to achieve an advantageous mid-plane position relative to the ovoids 112, 114.
  • Retractor balloons 130, 132 are preferably added to the intracavitary brachytherapy applicator to retract the bladder and the rectum from the radiation sources, thus lowering the dose to these critical structures. This can reduce, and in some cases eliminate, the need to use of vaginal packing after the applicator is in place.
  • the retractor balloons 130, 132 are coupled to catheters 184, 186 that are preferably anchored on the ovoid assembly 110.
  • the retractor balloons 130, 132 are preferably inflated with saline. Other suitable inflation mediums can also be used.
  • the balloons can be semi-cylindrical or semi-ellipsoide when inflated to push the vaginal mucosa, bladder, and rectum away from the radiation site.
  • Balloons having other suitable shapes and sizes for providing retraction can also be used.
  • the retraction mechanism is preferably inflatable to retract the bladder and the rectum by at least about 2 cm away from a plane of the implant defined at the plane of the tandem bisecting the ovoids.
  • the retraction mechanism preferably retracts equidistance from the plane of the implant.
  • the retraction mechanism comprises balloons 130, 132 and retractor supports 174, 176 coupled to the ovoid assembly 110 at retractor connection portions 134, 136.
  • the applicator system 100 can comprise environmentally friendly, disposable and/or recyclable materials.
  • plastics such as Delrin, Peek, GlassPeek, etc. can be used.
  • Stainless steel or other suitable materials can be used.
  • allergy causing materials such as latex can be avoided.
  • Balloon materials are preferably very strong, such as, for example, a double-layered polyurethane to avoid leaking and/or bursting.
  • the applicator is made of MRI and CT friendly materials.
  • radiographic markers can be provided along the catheters. Radiographic markers can be used to identify left and right ovoids 112, 114 by varying the number or style of markings 120, 122 on each ovoid. Radiographic markers can be provided on the external surfaces of the ovoid balloons 112, 114 to identify their placements and ensure proper expansion while being treated. Radiographic markers 106 can be provided on the tandem spaced one-cm apart to measure the length of the tandem 102 and/or to measure the magnification factor on the orthogonal radiographs.
  • the applicator system preferably is adapted to be gamma ray, and gas sterilizable.
  • the catheters of the applicator are preferably numbered and marked as corresponding to 1.
  • the Luer Lock 182 inflating the Right Ovoid, 4.
  • the Luer Lock 180 inflating the Left Ovoid, 5.
  • the Luer Locks 184, 186 to inflate the retraction mechanism - one for the bladder and one for the rectum.
  • the applicator 100 can be connected via three equal length transfer guide tubes or catheters 138, 140, 142 to the high dose brachytherapy afterloader with a 192-Iridium High Dose Rate (HDR) radioactive source.
  • the transfer guide tubes 138, 140, 142 can vary in length.
  • the three transfer guide tubes 138, 140, 142 are coupled to the tandem 102 and the pair of inflatable ovoids 112, 114.
  • a similarly designed applicator can be used with either 137-Cs tubes or 192-Iridium ribbons (192Ir seeds on a wire) placed inside plastic transfer guide tubes 138, 140, 142.
  • the internal diameters of the tandem and the ovoids will be adjusted relative to the HDR applicator design to accommodate the commercially available 137-Cs tubes.
  • 192-Iridium ribbons the same tandem and ovoids designed for HDR can be used without any modifications to the internal diameter of the tandem and the ovoid catheters.
  • Other parameters and characteristics of the applicator can be similar to those described for the HDR applicator.
  • the LDR and HDR isodose distributions are preferably similar to the conventional FSD tandem and ovoids implants, yielding similar doses to the treatment site.
  • a miniaturized endoscopic fiber optic bundle 190 is integrated with the tandem 102.
  • the fiber optic bundle 190 can be about 1 mm thick along the length of the tandem 102.
  • the endoscope 104 can be illuminated by a battery operated LED light and connected to a CCD camera. The images preferably can be seen on a display monitor or be captured in a laptop computer connected through a USB2 connector, or other suitable connector, for further analysis.
  • the eye piece can be attached to a coupler that can be attached to a CCD camera and connected to a laptop computer or a display monitor.
  • Endoscopic capabilities of the tandem 102 enables the physician to find the cervical os, guide the tandem into the cervical os and uterine canal, sound the uterus, and inspect the extent of the disease in vagina, cervix, uterine canal, and the uterus.
  • the endoscope 104 can help the radiation oncologist to guide the tandem to the end of the uterine canal without perforating it.
  • a mechanism, such as markings on the tandem 106 can be used to measure the length of the uterine canal from the cervical os to the end of the canal. This feature helps sound the uterine canal and position the flange on the tandem to limit the risk of the tandem perforating the uterus.
  • the applicator 100 comprises a tandem catheter adapted to be placed in the uterine canal with a cervical os stopper (e.g., a flange with a ring radiographic marker).
  • the ovoid and retractable system assembly (collectively, ORSA) is preferably coupled prior to treatment to form an integrated unit as one part.
  • the ORSA can be inserted after the tandem is in place.
  • the tandem preferably slides through a central pivoting tract between the two ovoids of the ORSA.
  • the ORSA is inserted inside the vaginal canal until it reaches the cervical fornices.
  • a separator mechanism on the ORSA can be adjusted to open and separate horizontally the two ovoids and lock at the desired position with a locking knob.
  • the inflatable ovoids can be filled with a mixture of saline, and 2% iodinated contrast solution through the luer lock for each ovoid.
  • the ovoids are filled symmetrically.
  • the saline volume will be dependent on the size of the fornices, and vaginal distal circumferential diameter.
  • the inflatable ovoids are preferably made such that there is at least one cm distance posteriorly from the end of the catheter to the surface of the vaginal mucosa, thus lowering the dose to the vaginal mucosa and rectum.
  • the adjustable volume of the ovoids and bigger diameter will conform to the shape of the fornices and improve the percentage depth dose to the tumor under treatment.
  • the pivoting tandem mechanism can be fixed so the tandem bisects the ovoids and remains locked using a side locking knob.
  • the square-shaped or flattened portion of the tandem is placed in the ovoid tract having a similar square-shaped or flattened configuration. This acts to limit the tandem from unwanted rotation in the uterine canal. Other shapes can be used to limit rotation of the tandem.
  • the two inflatable retractors are filled with saline to retract the anterior and posterior wall of the vaginal canal from the plane of the implant.
  • the retractors can be filled symmetrically in some embodiments.
  • the volume of the saline is adjusted to preferably have at least two cm retraction from the plane of the tandem.
  • An advantage of an embodiment wherein the inflatable retractors are made of soft polyurethane semi-cylindrical or disc-shaped balloons is that the patient will feel less pain and little pressure. Since insertion of the tandem is followed by the insertion of the assembled single piece ovoid and retractor assembly, the implant time is much shorter compared with devices that require assembly of several components in the patient. Accordingly, patient discomfort and pain is minimal, lowering the need for complete and prolonged anesthetics. Due to adjustable features of the applicator, most of the positioning and adjustments is done remotely outside uterus, cervix, and vagina, making it minimally invasive, lowering patient pain and discomfort and number of personnel required for assistance.
  • the applicator is designed to have markers every one centimeter for radiographic identification and has magnification factors readily available for dose calculations.
  • the disposable material made of high strength plastics (Peek, GlassPeek) or lightweight stainless steel has minimal radiation self absorption, removing the need for dosimetry corrections.
  • the total length of the three catheters is preferably substantially identical to limit human errors during dosimetry calculations.
  • the applicator is designed such that the right ovoid will be connected through a transfer guide tube to channel one, the left ovoid to channel two, and the tandem to channel three of a commercially available 192-Ir HDR afterloader.
  • the tandem and ovoid system preferably comprises CT and MRI friendly material, making 3D dosimetry possible with no image artifacts.
  • the patient can then be allowed to heal.
  • the recovery time is reduced compared to conventional treatments due to the improved dosimetry and limited invasiveness of the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Radiation-Therapy Devices (AREA)

Claims (14)

  1. System zur Behandlung von Gebärmutterhals- bzw. Gebärmutterkrebs mittels Brachytherapie mit einem intrakavitären Brachytherapie-Applikator (100), umfassend:
    ein Tandem (102), dafür ausgelegt, in den Gebärmutterhals einer Patientin eingebracht zu werden;
    eine ovoide Anordnung (110), umfassend erste und zweite aufblasbare Ovoide (112, 114) und einen Ovoidstützmechanismus (116), wobei die ersten und zweiten aufblasbaren Ovoide (112, 114) zur Einbringung in das Scheidengewölbe einer Patientin ausgelegt sind; und erste und zweite Wundhaken (130, 132), die dafür ausgelegt sind, mit der ovoiden Anordnung (110) gekoppelt zu werden, wobei der erste Wundhaken (130) so platziert werden kann, um die Blase einer Patientin während der Behandlung zurückzuziehen, und der zweite Wundhaken (132) so positioniert werden kann, um das Rektum einer Patientin während der Behandlung zurückzuziehen;
    wobei das Tandem (102) und die ersten und zweiten aufblasbaren Ovoide (112, 114) dafür ausgelegt sind, mit einer radioaktiven Quelle gekoppelt zu werden, um eine implantierte Strahlendosis zu liefern, die zur Krebsbehandlung einer kanzerogen Behandlungsstelle in einer Patientin geeignet ist.
  2. System nach Anspruch 1, wobei das Tandem (102) ein endoskopisches Betrachtungselement (104) umfasst, um die Positionierung des Tandems (102) zu erleichtern.
  3. System nach Anspruch 1, wobei das Tandem (102) einen oder mehrere radiografische Marker (106) umfasst.
  4. System nach Anspruch 1, wobei der Ovoidstützmechanismus (116) dafür ausgelegt ist, die Ovoide (112, 114) zu stützen und eine Benutzerbedienung zu ermöglichen, um die relative Position der Ovoide (112, 114) beim Einbringen der Ovoide (112, 114) in das Scheidengewölbe einer Patientin zu kontrollieren.
  5. System nach Anspruch 1, wobei die ersten und zweiten aufblasbaren Ovoide (112, 114) einstellbar aufblasbar sind und eine luftleere Konfiguration für das Einbringen in eine Patientin haben sowie eine oder mehrere einstellbare aufblasbare Konfigurationen für die Positionierung der ovoiden Anordnung während der Behandlung haben.
  6. System nach Anspruch 1, wobei die ersten und zweiten Ovoide (112, 114) jeweils einen oder mehrere radiografische Marker (120, 122) haben.
  7. System nach Anspruch 1, wobei die ovoide Anordnung (110) einen Tandemverbinder (124) umfasst, der dafür ausgelegt ist, das Tandem (102) lösbar und einstellbar mit der ovoiden Anordnung (110) zu koppeln.
  8. System nach Anspruch 1, wobei die ovoide Anordnung (110) einen Tandemverbinder (124) umfasst, der dafür ausgelegt ist, eine Schwenkbewegung des Tandems (102) relativ zur ovoiden Anordnung (110) zu ermöglichen.
  9. System nach Anspruch 1, wobei die ovoide Anordnung (110) einen Tandemverbinder (124) umfasst, der dafür ausgelegt ist, eine Translationsbewegung des Tandems (102) relativ zur ovoiden Anordnung (110) zu ermöglichen.
  10. System nach Anspruch 1, wobei die ovoide Anordnung (110) einen Tandemverbinder (124) umfasst, der dafür ausgelegt ist, eine Drehbewegung des Tandems (102) um eine Längsachse des Tandems (102) zu begrenzen.
  11. System nach Anspruch 1, wobei die ersten und zweiten Wundhaken (130, 132) dafür ausgelegt sind, lösbar mit der ovoiden Anordnung (110) an ersten und zweiten Wundhaken-Verbinderabschnitten (134, 136) gekoppelt zu werden.
  12. System nach Anspruch 1, wobei die ersten und zweiten Wundhaken (130, 132) aufblasbar sind.
  13. System nach Anspruch 1, wobei die ersten und zweiten Wundhaken (130, 132) einstellbar aufblasbar sind und eine luftleere Konfiguration für das Einbringen in eine Patientin haben sowie eine oder mehrere einstellbare aufblasbare Konfigurationen für das Zurückziehen von Gewebe während der Behandlung haben.
  14. System nach Anspruch 1, das alle Eigenschaften der Ansprüche 2 bis 13 umfasst.
EP10802986.9A 2009-07-24 2010-07-23 System zur behandlung von krebs mittels einer brachytherapie Active EP2456520B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27177409P 2009-07-24 2009-07-24
PCT/US2010/043121 WO2011011731A2 (en) 2009-07-24 2010-07-23 Systems and methods for treating cancer using brachytherapy

Publications (3)

Publication Number Publication Date
EP2456520A2 EP2456520A2 (de) 2012-05-30
EP2456520A4 EP2456520A4 (de) 2015-12-30
EP2456520B1 true EP2456520B1 (de) 2017-07-19

Family

ID=43499679

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10802986.9A Active EP2456520B1 (de) 2009-07-24 2010-07-23 System zur behandlung von krebs mittels einer brachytherapie

Country Status (3)

Country Link
US (1) US9295491B2 (de)
EP (1) EP2456520B1 (de)
WO (1) WO2011011731A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295856B2 (en) 2009-07-24 2016-03-29 Voxel Rad, Ltd. Systems and methods for treating cancer using brachytherapy
US8579785B2 (en) 2011-05-10 2013-11-12 Nazly Makoui Shariati Source/seed delivery surgical staple device for delivering local source/seed direclty to a staple margin
CN103648586A (zh) * 2011-07-01 2014-03-19 米克放射原子能设备公司 具有可交换和/或可滑动的钨护罩的膀胱和/或直肠延长器
US9345907B2 (en) 2011-07-01 2016-05-24 Mick Radio-Nuclear Instruments, Inc. Bladder and/or rectum extender with exchangeable and/or slideable tungsten shield
US8979725B2 (en) * 2012-05-23 2015-03-17 Mark A. D'Andrea Brachytherapy tandem and ovoid implantation devices and methods
WO2014036337A2 (en) * 2012-08-29 2014-03-06 Fillmore Spencer J Brachytherapy applicator device and method of use thereof
NL2009697C2 (en) * 2012-10-25 2014-04-29 Nucletron Operations Bv A modular applicator for brachytherapy.
EP2745875B1 (de) * 2012-12-19 2016-05-25 Voxel Rad, Ltd. Systeme zur Behandlung von Krebs mit Brachytherapie
US10245446B2 (en) 2013-03-14 2019-04-02 University Of Iowa Research Foundation Marker-flange for MRI-guided brachytherapy
US9180311B2 (en) 2013-08-29 2015-11-10 Kobold, Llc Brachytherapy applicator device and method of use thereof
US10086213B2 (en) 2015-04-23 2018-10-02 Mark A. D'Andrea Mobile gynecological balloon devices and methods
CN105148391B (zh) * 2015-10-10 2018-06-22 中国医学科学院北京协和医院 一种施源驻留器阴道口固定装置
US10525282B2 (en) 2015-10-15 2020-01-07 Kobold, Llc Brachytherapy ring applicator device and method of use thereof
US9808649B2 (en) * 2016-01-07 2017-11-07 Medical Tool & Technology, Llc Immobilization system to support an in vivo medical device
CN106621008A (zh) * 2017-01-24 2017-05-10 周洁晶 阴道球囊扩充装置
EP3403603A1 (de) * 2017-05-15 2018-11-21 Contract Medical International GmbH Brachytherapiesatz
US10806339B2 (en) * 2018-12-12 2020-10-20 Voxel Rad, Ltd. Systems and methods for treating cancer using brachytherapy
CN109847166B (zh) * 2019-03-14 2021-04-30 潍坊市妇幼保健院 一种妇产科专用宫颈麻醉装置

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888917A (en) * 1954-09-08 1959-06-02 Radium Service Corp Of America Cervico-vaginal radium applicator
US4294264A (en) 1976-03-31 1981-10-13 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Cervix-to-rectum measuring device in a radiation applicator for use in the treatment of cervical cancer
US5012357A (en) 1989-03-20 1991-04-30 University Of Michigan CT compatible intracavity radiation applicator with afterloading shielding
US5562594A (en) 1994-06-10 1996-10-08 Duke University Shielded mini-applicator system for radioactive source treatment of cancer of the uterine cervix
US6482142B1 (en) 1997-07-24 2002-11-19 Proxima Therapeutics, Inc. Asymmetric radiation dosing apparatus and method
US6312375B1 (en) * 1998-08-07 2001-11-06 Joseph F. Montebello Inflatable covering for tandem colpostat intracavitary implant
US6390968B1 (en) 2000-06-07 2002-05-21 Paxton Equities, Llc Cervical applicator for high dose radiation brachytherapy
US6746465B2 (en) 2001-12-14 2004-06-08 The Regents Of The University Of California Catheter based balloon for therapy modification and positioning of tissue
US20040006305A1 (en) * 2002-07-03 2004-01-08 Stephen Hebert Balloon catheter having an expandable distal end
US7338430B2 (en) 2003-06-18 2008-03-04 Xoft, Inc. Gynecological brachytherapy applicator and system
US7556596B2 (en) * 2004-07-20 2009-07-07 Board Of Regents The University Of Texas System Adaptive intracavitary brachytherapy applicator
US7534202B2 (en) * 2004-10-04 2009-05-19 Board Of Regents, The University Of Texas System System and method for high dose rate radiation intracavitary brachytherapy
US7666130B2 (en) * 2006-06-21 2010-02-23 Mick Radio-Nuclear Instruments, Inc. Split-ring brachytherapy device and method for cervical brachytherapy treatment using a split-ring brachytherapy device
WO2008124149A1 (en) 2007-04-10 2008-10-16 University Of Toledo Intracavitary radiation system
US7678040B2 (en) 2007-05-31 2010-03-16 Xoft, Inc. Customized gynecological brachytherapy applicator and method
US8636635B2 (en) 2008-08-18 2014-01-28 Cianna Medical, Inc. Brachytherapy apparatus, systems, and methods for using them
US8500618B2 (en) * 2008-09-11 2013-08-06 Radiadyne, Llc Dual gynecological balloon packing system

Also Published As

Publication number Publication date
EP2456520A2 (de) 2012-05-30
WO2011011731A3 (en) 2011-06-16
EP2456520A4 (de) 2015-12-30
US20120123188A1 (en) 2012-05-17
WO2011011731A2 (en) 2011-01-27
US9295491B2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
EP2456520B1 (de) System zur behandlung von krebs mittels einer brachytherapie
US20230085476A1 (en) Systems and methods for treating cancer using brachytherapy
US6641518B2 (en) Multicomponent vaginal cylinder system for low dose rate brachytherapy or gynecological cancers
US8961383B2 (en) Intracavitary radiation system
US11617503B2 (en) Systems and methods for treating cancer using brachytherapy
US8033979B2 (en) Split-ring brachytherapy device and method for cervical brachytherapy treatment using a split-ring brachytherapy device
EP2533847B1 (de) Brachytherapie-applikator
US7534202B2 (en) System and method for high dose rate radiation intracavitary brachytherapy
ES2367407T3 (es) Procedimiento y equipo para la administración de braquiterapia a un sujeto.
US20140121445A1 (en) Intracavitary Brachytherapy Device for Insertion in a Body Cavity and Methods of Use Thereof
US20090234178A1 (en) Systems and methods for delivering radiation therapy
EP2745875B1 (de) Systeme zur Behandlung von Krebs mit Brachytherapie
US20240115880A1 (en) Applicators, systems, devices and methods for cervical brachytherapy
CN214018951U (zh) 一种直肠腔内可调整多通道弧形后装施源器

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20151202

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 3/04 20060101ALI20151126BHEP

Ipc: A61N 5/01 20060101AFI20151126BHEP

Ipc: A61M 36/04 20060101ALI20151126BHEP

Ipc: A61N 5/10 20060101ALI20151126BHEP

Ipc: A61M 36/10 20060101ALI20151126BHEP

Ipc: A61B 18/00 20060101ALI20151126BHEP

Ipc: A61B 17/02 20060101ALI20151126BHEP

Ipc: A61N 5/00 20060101ALN20151126BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 36/10 20060101ALI20161125BHEP

Ipc: A61B 18/00 20060101ALI20161125BHEP

Ipc: A61B 17/02 20060101ALI20161125BHEP

Ipc: A61N 5/10 20060101ALI20161125BHEP

Ipc: A61M 36/04 20060101ALI20161125BHEP

Ipc: A61N 5/00 20060101ALN20161125BHEP

Ipc: A61N 5/01 20060101AFI20161125BHEP

Ipc: A61M 3/04 20060101ALI20161125BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170201

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 909807

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170815

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010043772

Country of ref document: DE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 909807

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171020

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171119

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171019

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010043772

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

26N No opposition filed

Effective date: 20180420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170723

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20200714

Year of fee payment: 11

Ref country code: FR

Payment date: 20200716

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200824

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210723

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230616

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240718

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240730

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240716

Year of fee payment: 15